8legs: International aids vaccine initiative (iavi)

#1 out of 1

Three Ebola vaccines in development amid growing outbreak fears

Vaccine development is active for Bundibugyo Ebola as new outbreaks raise concerns in DR Congo and Uganda.
IAVI is adapting its vaccine approach to fight Bundibugyo during the ongoing outbreak.
Moderna uses mRNA technology to target Bundibugyo Ebola as part of the response.
Oxford is developing a new vaccine platform with trials expected in two to three months.
Cepi funds early-stage research to accelerate vaccine development.
Experts warn every day counts as the outbreak grows in the region.
MSF cautions the situation is deeply alarming as cases rise quickly.
Vaccine development targets Bundibugyo, a less common Ebola species with limited vaccines.
No licensed Bundibugyo vaccine exists yet as the outbreak expands.
The outbreak in DR Congo has triggered international attention and funding.

Vote 0